FDA CDRH Portal Now Offers Tracking of Pre-Submissions
On May 22, the FDA announced that it has updated the CDRH Portal to allow users to track the progress of Pre-Submissions. A submitter must specify the type of Pre-Submission request, which include:
- written feedback (only)
- written feedback followed by a meeting
The agency noted that the CDRH Portal updates are a step forward in meeting the Medical Device User Fee Amendments 2022 (MDUFA V) commitments of using technology to enhance efficiency and transparency in reviewing industry submissions.
All CDRH-led premarket submission types may be uploaded to the CDRH Portal at any stage of the review process. Official correspondents do not need to send a physical cover letter to the FDA after uploading an electronic submission to the CDRH Portal.
Starting October 1, 2023, all 510(k) submissions must be submitted as electronic submissions using eSTAR, unless exempted in Section VI.A Waivers and Exemptions From Electronic Submission Requirements of the Electronic Submission Template for Medical Device 510(k) Submissions guidance.
Prior to October 1, 2023, companies may submit 510(k)s by mail or through the CDRH Portal in either the eSTAR or eCopy format. De Novo requests submitted using eSTAR remain voluntary until further notice.
Related Articles
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
-
The voluntary program is designed to help companies advance alternative and innovative ways to sterilize approved medical devices, including changing radiation sources, in a least burdensome regulatory approach.
-
“Content of Premarket Submissions for Device Software Functions” covers recommended documentation sponsors should include in premarket submissions for FDA’s evaluation of safety and effectiveness of device software functions. The agency is hosting a webinar for industry on July 20 to…
-
Unhappy with current textbooks and resources for regulatory professionals, Elijah Wreh, Professor of Regulatory Science and Senior Manager Regulatory Affairs at Boston Scientific, authored his own book for industry and future regulators.
